X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Sun Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs DIVIS LABORATORIES - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUN PHARMA DIVIS LABORATORIES SUN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 15.0 17.8 84.3% View Chart
P/BV x 3.5 3.9 91.6% View Chart
Dividend Yield % 0.2 1.6 13.5%  

Financials

 SUN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    SUN PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
SUN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,2012,484 48.3%   
Low Rs706918 76.9%   
Sales per share (Unadj.) Rs117.5142.3 82.6%  
Earnings per share (Unadj.) Rs19.641.9 46.8%  
Cash flow per share (Unadj.) Rs23.846.3 51.4%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %0.10.6 17.8%  
Book value per share (Unadj.) Rs130.5161.5 80.8%  
Shares outstanding (eoy) m2,406.60265.47 906.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x8.112.0 67.9%   
Avg P/E ratio x48.740.6 119.8%  
P/CF ratio (eoy) x40.136.7 109.1%  
Price / Book Value ratio x7.310.5 69.4%  
Dividend payout %5.123.9 21.4%   
Avg Mkt Cap Rs m2,294,813451,525 508.2%   
No. of employees `00014.73.7 397.7%   
Total wages/salary Rs m47,9713,649 1,314.6%   
Avg. sales/employee Rs Th19,169.810,184.4 188.2%   
Avg. wages/employee Rs Th3,253.0984.1 330.5%   
Avg. net profit/employee Rs Th3,197.92,998.5 106.6%   
INCOME DATA
Net Sales Rs m282,69737,764 748.6%  
Other income Rs m6,170848 727.2%   
Total revenues Rs m288,86738,612 748.1%   
Gross profit Rs m83,23914,138 588.8%  
Depreciation Rs m10,1351,182 857.6%   
Interest Rs m4,76923 20,555.6%   
Profit before tax Rs m74,50513,781 540.6%   
Minority Interest Rs m-11,1260-   
Prior Period Items Rs m-190-   
Extraordinary Inc (Exp) Rs m-6,8520-   
Tax Rs m9,3492,662 351.1%   
Profit after tax Rs m47,15911,119 424.1%  
Gross profit margin %29.437.4 78.7%  
Effective tax rate %12.519.3 65.0%   
Net profit margin %16.729.4 56.7%  
BALANCE SHEET DATA
Current assets Rs m308,64630,947 997.4%   
Current liabilities Rs m132,4775,195 2,550.1%   
Net working cap to sales %62.368.2 91.4%  
Current ratio x2.36.0 39.1%  
Inventory Days Days83117 71.0%  
Debtors Days Days8885 103.1%  
Net fixed assets Rs m133,60617,027 784.7%   
Share capital Rs m2,407531 453.3%   
"Free" reserves Rs m266,90942,341 630.4%   
Net worth Rs m314,04242,877 732.4%   
Long term debt Rs m31,1675 663,134.0%   
Total assets Rs m542,19649,684 1,091.3%  
Interest coverage x16.6595.0 2.8%   
Debt to equity ratio x0.10 90,539.4%  
Sales to assets ratio x0.50.8 68.6%   
Return on assets %9.622.4 42.7%  
Return on equity %15.025.9 57.9%  
Return on capital %17.832.2 55.1%  
Exports to sales %14.085.3 16.4%   
Imports to sales %3.122.9 13.7%   
Exports (fob) Rs m39,57232,198 122.9%   
Imports (cif) Rs m8,8828,654 102.6%   
Fx inflow Rs m42,17132,270 130.7%   
Fx outflow Rs m21,5838,775 246.0%   
Net fx Rs m20,58823,496 87.6%   
CASH FLOW
From Operations Rs m67,69410,379 652.2%  
From Investments Rs m-44,549-4,135 1,077.4%  
From Financial Activity Rs m-19,243-6,241 308.3%  
Net Cashflow Rs m3,9023 118,227.3%  

Share Holding

Indian Promoters % 63.7 52.0 122.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 5.1 11.8 43.5%  
FIIs % 23.0 19.0 121.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.3 17.2 48.3%  
Shareholders   133,026 31,796 418.4%  
Pledged promoter(s) holding % 0.5 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUN PHARMA With:   ELDER PHARMA  FDC LTD.  SHASUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare SUN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Post Noon Sell-Off; Infosys Falls 5.4%(Closing)

Share markets in India witnessed a sharp fall in the final minutes of trade. At the closing bell, the BSE Sensex closed lower by 266 points. While, the NSE Nifty finished lower by 83 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Aug 21, 2017 (Close)

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS